Wednesday, August 20, 2014

An experimental serum that still need to study

An experimental serum that still need to study

That is why a private laboratory based in San Diego, Mapp Biopharmaceutical, has developed a cocktail of antibodies called ZMapp. This potential treatment has never been tested on a large scale in humans . But recently, two people infected with Ebola were repatriated to the United States to receive that to which they responded well, unlike a Spanish priest who received the same treatment experimental serum.

We know that the treatment ZMapp has three antibodies that prevent infection of cells by the Ebola virus. He had been tested on monkeys in experiments that have been published in 2012 in PNAS .

Although it seems effective, at least when administered shortly after infection, it remains experimental. The use of this treatment has been controversial: is it ethically responsible to administer to sick knowing he is not licensed? Side effects, especially, are not known. However, given the seriousness of the epidemic, the WHO has therefore decided that it was better to use it.

In parallel, research is still working on this treatment: for example, the laboratories of Scripps Research Institute are studying the antibodies that could fight the Ebola virus, the three antibodies in the serum ZMapp. TSRI laboratories studying the structures of these antibodies by electron microscopy and crystallography to X-rays in these images. Thanks, researchers are trying to better understand how these antibodies bind to Ebola virus and prevent it from operating. Erica Ollmann Saphire According researcher at TSRI, this experimental treatment would be one of the best currently known antibody cocktails, but there may be ways to improve it ...

No comments:

Post a Comment